CL2013003785A1 - Use of necrostatin-1 for the treatment of axonal degeneration induced by acute and chronic damage - Google Patents

Use of necrostatin-1 for the treatment of axonal degeneration induced by acute and chronic damage

Info

Publication number
CL2013003785A1
CL2013003785A1 CL2013003785A CL2013003785A CL2013003785A1 CL 2013003785 A1 CL2013003785 A1 CL 2013003785A1 CL 2013003785 A CL2013003785 A CL 2013003785A CL 2013003785 A CL2013003785 A CL 2013003785A CL 2013003785 A1 CL2013003785 A1 CL 2013003785A1
Authority
CL
Chile
Prior art keywords
necrostatin
acute
treatment
axonal degeneration
chronic damage
Prior art date
Application number
CL2013003785A
Other languages
Spanish (es)
Inventor
Alarcon Washington Nicolas Martinez
Goldsmith Felipe Alfredo Court
Original Assignee
Univ Pontificia Catolica Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pontificia Catolica Chile filed Critical Univ Pontificia Catolica Chile
Priority to CL2013003785A priority Critical patent/CL2013003785A1/en
Publication of CL2013003785A1 publication Critical patent/CL2013003785A1/en
Priority to ARP140104692A priority patent/AR098778A1/en
Priority to PCT/CL2014/000084 priority patent/WO2015100511A1/en
Priority to UY0001035921A priority patent/UY35921A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
CL2013003785A 2013-12-30 2013-12-30 Use of necrostatin-1 for the treatment of axonal degeneration induced by acute and chronic damage CL2013003785A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CL2013003785A CL2013003785A1 (en) 2013-12-30 2013-12-30 Use of necrostatin-1 for the treatment of axonal degeneration induced by acute and chronic damage
ARP140104692A AR098778A1 (en) 2013-12-30 2014-12-16 METHOD AND USE OF NECROSTATIN-1 FOR THE TREATMENT OF AXONAL DEGENERATION INDUCED BY ACUTE AND CHRONIC DAMAGES
PCT/CL2014/000084 WO2015100511A1 (en) 2013-12-30 2014-12-23 Method and use of necrostatin-1 for treating axonal degeneration caused by acute and chronic damage
UY0001035921A UY35921A (en) 2013-12-30 2014-12-24 NECROSTATIN-1 AND DERIVATIVES AS RETAINERS OF AXONAL DEGENERATION

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2013003785A CL2013003785A1 (en) 2013-12-30 2013-12-30 Use of necrostatin-1 for the treatment of axonal degeneration induced by acute and chronic damage

Publications (1)

Publication Number Publication Date
CL2013003785A1 true CL2013003785A1 (en) 2014-07-11

Family

ID=53492873

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013003785A CL2013003785A1 (en) 2013-12-30 2013-12-30 Use of necrostatin-1 for the treatment of axonal degeneration induced by acute and chronic damage

Country Status (4)

Country Link
AR (1) AR098778A1 (en)
CL (1) CL2013003785A1 (en)
UY (1) UY35921A (en)
WO (1) WO2015100511A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11382889B2 (en) 2018-04-19 2022-07-12 Institut D'investigació Biomèdica De Bellvitge (Idibell) NRF2 activators for the prevention and/or treatment of axonal degeneration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009521454A (en) * 2005-12-20 2009-06-04 プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ Compounds, screening, and methods of treatment
CA2888805C (en) * 2011-10-21 2020-07-14 Massachusetts Eye And Ear Infirmary Methods and compositions for promoting axon regeneration and nerve function

Also Published As

Publication number Publication date
WO2015100511A1 (en) 2015-07-09
AR098778A1 (en) 2016-06-15
UY35921A (en) 2015-06-30

Similar Documents

Publication Publication Date Title
ES2811327T8 (en) Use of cannabinoids in the treatment of atonic seizures in Lennox-Gastaut syndrome
BR112015028171A2 (en) acc inhibitors and their use
CO6791602A2 (en) Methods and systems for the treatment of wells
BR112015001712A2 (en) use of s-pindolol for the treatment of cachexia and sarcopenia
BR112017004451A2 (en) stone paint formulation and methods to produce the same
DK3116897T3 (en) Polymyxin derivatives and their use in combination therapy with various antibiotics
BR112016008886A2 (en) SUPPORT ELEMENT FOR THE HUMAN BODY
FR3024945B1 (en) ABSORBENT ARTICLE WITH GRAPHICS
BR112017003964A2 (en) top sheet for absorbent article
BR112014027953A2 (en) nifuratel- (r), its use for the treatment of infections and synthesis of nifuratel - (r) and - (s)
ES2965906T3 (en) Peptides for use in the treatment of oral mucositis
CL2015000537A1 (en) Siarn and its use in methods and compositions for the treatment and / or prevention of eye diseases.
BR112017001384A2 (en) compound for use in anthelmintic treatment
CL2015003620A1 (en) Compositions for postharvest treatment and related methods
DK3193936T3 (en) Antimicrobials with increased effect
BR112016021620A2 (en) compounds and their methods of use
BR112015021722A2 (en) composition for use in the treatment of polycystic ovary syndrome
ES2759940T8 (en) 1,3,4-Thiadiazole compounds and their use to treat cancer
DK3259383T3 (en) TIN-NICKEL LAYER WITH HIGHER HARDNESS
ITUB20156000A1 (en) Nematocidal composition and its use
CL2013003785A1 (en) Use of necrostatin-1 for the treatment of axonal degeneration induced by acute and chronic damage
ES1094613Y (en) Vacuum device for the elimination of parasites present in the hair.
ES1084879Y (en) SECURITY DEVICE FOR THE USE OF ELEMENTS THAT ARE HANDLED IN SUSPENSION
CL2014003074A1 (en) Hybrid material of polymer-metal nanoparticles; method to prepare the material; and use of said material.
ES1142736Y (en) TOILET FOR VEHICLES AND SIMILAR